Fig. 3
PTH1-34 reduction of soluble Aβ level and in-soluble Aβ deposition in 5XFAD brain. A Illustration of PTH1-34 intermittent treatment in 5XFAD mice. Mice were sacrificed at 5 ~ MO old to detect Aβ level and accumulation. B, C ELISA analyses of human Aβ40(B) and Aβ42(C) levels in the soluble fraction of brain homogenates including cortex and hippocampus (200 μg total protein) from female 5XFAD mice with PTH1-34 or Veh treatment (n = 4 mice per group). D, E Representative images of ThioS staining for Aβ plaque depositions analysis in the cortex and hippocampus of 5XFAD-Veh (control) and 5XFAD-PTH1-34 mice. Representative images of female mice were shown in D and representative images of male mice were shown in E. F, G Quantification of plaque density (the amount of plaque deposition in each sub-region) in the cortex of 5XFAD female and male mice. H Quantification of the total plaque density in the cortex of female and male 5XFAD mice. I, J Quantification of plaque density in subregions of hippocampus in 5XFAD female and male mice. K Quantification of the total plaque density in the hippocampus of female and male 5XFAD mice. L Quantification of average plaque size in 5XFAD female and male mice. n = 8 per group for female mice and n = 6 per group for male mice in F–L. Scale bars as indicated in each panel. All data were presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, two-way ANOVA with Sidak’s multiple comparisons test was used